Emerging biotechnologies are once again catching investors’ attention as more and more monkeypox cases are reported. In fact, earlier this week, WHO announced a global health emergency regarding the rapid increase in the Monkeypox spread. Taking into consideration the rising cases and awareness of the disease, it is highly likely that government funds will start to flow into companies with approved vaccines & manufacturing capacity.
In this article, we look at GeoVax Labs, Inc. (NASDAQ: GOVX), SIGA Technologies, Inc. (NASDAQ: SIGA), and Aethlon Medical, Inc. (NASDAQ: AEMD) and all the reasons why they are among the top Monkeypox stocks to play ahead of a potential pandemic.
Monkeypox Stocks To Buy #1: GOVX
GeoVax Labs, Inc. (NASDAQ: GOVX) is a biotechnology company focused on developing human vaccines & immunotherapies against infectious diseases and cancer. Its now flagship product – MVA-VLP-SUDV, combines the advantages of the immunogenicity of a live attenuated vaccine vector with the authentic conformation of virus-like particles (VLPs). It also has ideal vaccine properties that will support use in the general population.
In light of this advanced development, GOVX Chief Scientific Officer – Mark J. Newman – is bullish saying:
“The MVA-VLP platform allows for the design of vaccines to present the immune system with multiple viral proteins in the conformation that mimics the actual virus. The resulting immune responses are broadly functional, involving both the antibody and T-cell effector function, resulting in optimal levels of efficacy, even with a single dose.
On July 28th, the company announced the publication of a peer-reviewed animal efficacy study of its modified vaccine Ankara (MVA) vectored vaccine against Sudan ebolavirus (SUDV). CEO David Dodd, believes this publication “further validates the broad utility and benefit of the GOVX’s MVA-VLP approach towards providing single-dose, highly efficacious vaccines against major infectious health challenges worldwide.”
The company has already major financial and production progress in the previous quarter and has assured investors of upcoming updates. Many are bullish any updates could push GOVX beyond its current resistance point very soon….
Currently, GOVX is trading at $1.98 with a near resistance at 2.35. The stocks shows an immediate support at 1.79 and another at .63. Accumulation has been steady for the past couple of weeks as the stock traded near its secondary support point. However, it has recently fluctuated and is now on a downtrend. MACD is bearish but seems poised for another crossover soon. Meanwhile, the RSI is on a downtrend and is now holding at 57 – indicating the stock is relatively stable to trade.
Monkeypox Stocks To Buy #2: SIGA
As a commercial-stage pharma, SIGA Technologies, Inc. (NASDAQ: SIGA) is focused on the health security market. Its lead product; TPOXX – an orally administered and IV formulation antiviral drug – is developed for the treatment of human smallpox disease caused by the variola virus. Approved by the FDA for the oral and IV formulation, TPOXX showed efficacy across all orthodox viruses as it works by blocking the virus from exiting infected cells.
In light of this progress, the US government has been stockpiling the drug since 2013, and in 2020, the company signed a $629 million 5-year contract and assured investors it will continue scaling up the production of TPOXX to meet the increasing demand and control the spread of monkeypox.
With this in mind, SIGA recently announced its plans to host a conference call on August 4th to update investors on its progress so far. Participating in the call will be CEO Dr. Phil Gomez, CFO Daniel Luckshire, and Chief Scientific Officer Dennis Hruby. Investors are bullish on the upcoming update given the company’s continous efforts to capitalize on the spread of monkeypox.
Since we alerted SIGA, the stock broke its previous resistance and showed MASSIVE growth! Currently trading at its newly formed resistance of $22.4, SIGA is on a run-up and shows no signs of stopping. The stock has strong support at 14.79 and 13.73. Accumulation has been on a steady run-up and shows no sign of a reversal. Similarly, the MACD is bullish and the the RSI is at 81 and trending upwards – indicating SIGA is now extrremely overbought.
Investors are bullish on the company’s progress in the past couple of months and are expecting promising updates & milestones regarding a monkeypox vaccine very soon. In anticipation of the company’s upcoming update call, SIGA is seeing new highs and continues to be one of the best monkeypox stocks to invest in. If you missed SIGA’s run? Sign up here & never miss another hot stock!
Monkeypox Stocks To Buy #3: AEMD
As a medical therapeutic company, Aethlon Medical, Inc. (NASDAQ: AEMD) is focused on developing products to diagnose & treat cancer and life threatening infectious diseases. The company hit multiple milestones this month. As of July 11th, AEMD announced DA approval of an amendment to the protocol of its ongoing clinical trial investigating the Aethlon Hemopurifier for patients with severe COVID-19.
More recently, the company announced the publication of a peer-reviewed journal article in PLOS ONE – another major milestone for AEMD. The article; “Removal of Clinically Relevant SARS-CoV-2 Variants by An Affinity Resin Containing Galanthus nivalis Agglutinin,” has data revealing that the proprietary GNA affinity resin of the Aethlon Hemopurifier efficiently captures 7 clinically relevant variants of the COVID-19 virus. With a viral capture efficiency ranging between 53% and 89% for the variants tested, AEMD’s Aethlon Hemopurifier has proven an effective and trusted treatment method.
Given the company’s ongoing efforts to diagnose & treat life threatning diseases, investors are watching AEMD closely as the Monkeypox spread continues to dominate many parts of the world.
Now trading at $1.08, AEMD has an immediate resistance near 1.09 and another at 1.2. The stock shows a near support at 1.05 and another at 1. Accumulation is heavily fluctuating and is now trending downwards. Similarly, the RSI is regulating and is now holding at 48. The MACD is bearish but seems poised for a reversal soon.
BOTTOM LINE
Monkeypox stocks are some of the hottest investments now as companies continue to compete in developing effective vaccines. Now that the disease is spreading across the globe, more and more companies are capitalizing on this. The 3 companies discussed in this article are taking real action towards dominating a quickly growing market and filling an urgent need. Given that these companies are potentially backed by government funds, investors who got in early on these monkeypox stocks could make BANK!! Get alerts on other emerging monkeypox stocks before anyone else!
As always, good luck to all (except the shorts)!
WHEN VIRAL STOCKS HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no business relationship with any company whose stock is mentioned in this video. Viral Stocks is not an investment advisor and this video does not provide investment advice. Always do your own research, make your own investment decisions, or consult with your nearest financial advisor. This video is not a solicitation or recommendation to buy, sell, or hold securities. This video is our opinion and is meant for informational and educational purposes only and does not provide investment advice. Past performance is not indicative of future performance.
